Loading clinical trials...
Loading clinical trials...
A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age
Conditions
Interventions
Darunavir
Ritonavir
Locations
8
Argentina
Buenos Aires, Argentina
Rio de Janeiro, Brazil
São Paulo, Brazil
Chennai, India
Kilifi, Kenya
Durban, South Africa
Start Date
September 1, 2009
Primary Completion Date
August 1, 2010
Completion Date
February 1, 2011
Last Updated
April 23, 2014
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions